S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
5 Reasons Why Amprius is About to Take Flight 
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
5 Reasons Why Amprius is About to Take Flight 
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
5 Reasons Why Amprius is About to Take Flight 
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
5 Reasons Why Amprius is About to Take Flight 
NASDAQ:VBLT

Vascular Biogenics (VBLT) Stock Forecast, Price & News

$0.22
-0.01 (-4.33%)
(As of 09/20/2023 ET)
Compare
Today's Range
$0.22
$0.23
50-Day Range
$0.21
$0.31
52-Week Range
$0.10
$0.32
Volume
208,279 shs
Average Volume
462,031 shs
Market Capitalization
$17.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

VBLT stock logo

About Vascular Biogenics (NASDAQ:VBLT) Stock

Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

VBLT Price History

VBLT Stock News Headlines

How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
Vascular Biogenics Rises on Presentation Hype
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
Vascular Biogenics (NASDAQ: VBLT)
Why Is Vascular Biogenics (VBLT) Stock Up 52%?
Vascular Biogenics Cutting About 35% of Staff >VBLT
See More Headlines
Receive VBLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vascular Biogenics and its competitors with MarketBeat's FREE daily newsletter.

VBLT Company Calendar

Last Earnings
8/14/2023
Today
9/20/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VBLT
Previous Symbol
NASDAQ:VBLX
Employees
7
Year Founded
N/A

Profitability

Net Income
$-32,300,000.00
Pretax Margin
-3,317.05%

Debt

Sales & Book Value

Annual Sales
$660,000.00
Book Value
$0.32 per share

Miscellaneous

Free Float
72,881,000
Market Cap
$17.16 million
Optionable
Optionable
Beta
0.82
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Prof. Dror Harats M.D. (Age 66)
    CEO & Director
    Comp: $444.33k
  • Mr. Samuel Backenroth (Age 39)
    Chief Financial Officer
    Comp: $410k
  • Dr. Eyal Breitbart Ph.D. (Age 56)
    Sr. VP of Research & Operations
  • Advocate Ayelet Horn (Age 52)
    Gen. Counsel
  • Dr. Erez Feige M.B.A. (Age 49)
    Ph.D., Sr. VP of Bus. Operations













VBLT Stock - Frequently Asked Questions

How have VBLT shares performed in 2023?

Vascular Biogenics' stock was trading at $0.12 at the beginning of 2023. Since then, VBLT shares have increased by 84.2% and is now trading at $0.2211.
View the best growth stocks for 2023 here
.

Are investors shorting Vascular Biogenics?

Vascular Biogenics saw a increase in short interest in August. As of August 31st, there was short interest totaling 296,700 shares, an increase of 46.8% from the August 15th total of 202,100 shares. Based on an average daily trading volume, of 1,260,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.5% of the shares of the stock are short sold.
View Vascular Biogenics' Short Interest
.

When is Vascular Biogenics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our VBLT earnings forecast
.

How were Vascular Biogenics' earnings last quarter?

Vascular Biogenics Ltd. (NASDAQ:VBLT) announced its earnings results on Monday, August, 14th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter.

What other stocks do shareholders of Vascular Biogenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include SCYNEXIS (SCYX), Matinas BioPharma (MTNB), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Aeterna Zentaris (AEZS), Dynavax Technologies (DVAX), Vaxart (VXRT) and Geron (GERN).

What is Vascular Biogenics' stock symbol?

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

Who are Vascular Biogenics' major shareholders?

Vascular Biogenics' stock is owned by many different retail and institutional investors. Top institutional investors include Simplex Trading LLC (0.00%).

How do I buy shares of Vascular Biogenics?

Shares of VBLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vascular Biogenics' stock price today?

One share of VBLT stock can currently be purchased for approximately $0.22.

How much money does Vascular Biogenics make?

Vascular Biogenics (NASDAQ:VBLT) has a market capitalization of $17.16 million and generates $660,000.00 in revenue each year. The biopharmaceutical company earns $-32,300,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis.

How can I contact Vascular Biogenics?

Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The official website for the company is www.vblrx.com. The biopharmaceutical company can be reached via phone at (728) 993-5000, via email at ir@vblrx.com, or via fax at 972-8993-5001.

This page (NASDAQ:VBLT) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -